Study of Myocardial Contractility After Cardiac Surgery Under an Anterograde or Retrograde Cardioplegia
NCT ID: NCT02816385
Last Updated: 2017-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2016-09-30
2017-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Cardioplegia are procedures to stop the contraction of myocardium. It is usually achieved with the use of chemicals ( cardioplegic solutions) or cold temperature (such as chilled perfusate). The composition of the cardioplegic solutions and their method of administration continuously changed over the years.
At the present date, cold blood cardioplegias are performed in the investigator's center. The investigators regularly use two modes of administration: either by an antegrade path (injection in the coronary arteries), or a retrograde one (injection in the venous system). At present, there are no elements supporting the superiority or inferiority of one path compared to another. The difficulty lies within a clear estimation of the contractility state of the ventricular cardiac muscle.
Technological developments in recent years provided a solution to this problem. The analysis of the pressure/volume curves generated by a ventricle allows an accurate quantification of the myocardial contractility. This requires the use of conductance catheters to accurately measure the ventricular volume and the ventricular pressure. The absolute ventricular contractility is then deduced with the help of a software.
The investigators intend to use this pressure-volume loops, obtained with conductance catheters, to compare the contractility of the right heart ventricle after antegrade vs retrograde cardioplegia.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antegrade Cardioplegia
Coronary artery bypass grafting (CABG) surgery in patients with a normal left ventricular ejection fraction (FEVG)
Antegrade cardioplegia
Injection of the cardioplegia in the coronary arteries
Retrograde Cardioplegia
Coronary artery bypass grafting (CABG) surgery in patients with a normal left ventricular ejection fraction (FEVG)
Retrograde cardioplegia
Injection of the cardioplegia in the venous system
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antegrade cardioplegia
Injection of the cardioplegia in the coronary arteries
Retrograde cardioplegia
Injection of the cardioplegia in the venous system
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal FEVG ( \> 50%)
Exclusion Criteria
* Associated procedures
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Brugmann University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pierre Wauthy
Head of clinic
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre Wauthy, MD, Pr
Role: PRINCIPAL_INVESTIGATOR
CHU Brugmann
Alessandro Falchetti, MD
Role: PRINCIPAL_INVESTIGATOR
CHU Brugmann
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Brugmann
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHUB-Retroplegie
Identifier Type: -
Identifier Source: org_study_id